Ads
related to: macular degeneration medication warnings treatment options- Wet AMD FAQs
Get Answers To Frequently Asked
Questions About Wet AMD
- Clinical Study Results
See The Results of A Clinical Study
To Learn More About This Treatment
- Appointment Tips
Get Tips And Useful Information
To Talk To Your Specialist
- Financial Assistance
Learn About Financial Support
That May Be Available To You
- Download The Amsler Grid
Use This Test To Help Monitor
Your Vision Between Appointments
- Resource Library
Tools To Understand Your Condition
Financial Support, and More
- Wet AMD FAQs
Search results
Results From The WOW.Com Content Network
These drugs are approved to treat neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy. View the ...
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF (/ v ɛ dʒ ˈ ɛ f /) therapy or medication, is the use of medications that block vascular endothelial growth factor. This is done in the treatment of certain cancers and in age-related macular degeneration.
The incidence of age-related macular degeneration and its associated features increases with age and is low in people <55 years of age. [101] Smoking is the strongest modifiable risk factor. [102] As of 2008, age-related macular degeneration accounts for more than 54% of all vision loss in the white population in the US. [103]
[8] [9] [11] In February 2023, the indication was updated to include the treatment of people with geographic atrophy secondary to age-related macular degeneration. [10] [20] The medication is given through a subcutaneous infusion for paroxysmal nocturnal hemoglobinuria and through intravitreal injection for age-related macular degeneration. [21]
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
Pegaptanib [2] sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). [3] It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States.
Ad
related to: macular degeneration medication warnings treatment options